Avenzo Therapeutics, founded by Athena Countouriotis and Mohammad Hirmand, seasoned veterans in the life science industry, is making waves in the field of oncology. Following Countouriotis' successful tenure as CEO of Turning Point Therapeutics, which was acquired by Bristol Myers Squibb for $4.1 billion, the duo embarked on a new venture to address unmet needs in cancer treatment. Avenzo Therapeutics, focuses on developing innovative solutions for hard-to-treat tumors, with a lead drug targeting resistance pathways in metastatic breast cancer and solid tumors. Avenzo’s recent success in excee ..read more

RA Capital Management, LP, renowned for its diverse investments in healthcare and expanding into other tech domains, has introduced a series of Exchange Traded Funds (ETFs) targeting the biotechnology sector. Among these, the flagship offering is the RA Best Biotech ETF (RABB), designed to capture the performance of core development-stage biotech companies favored by specialists. Notably, RABB's composition is informed by advanced artificial intelligence algorithms, reflecting RA Capital's commitment to data-driven investment strategies. In addition to RABB, RA Capital has launched innovative ..read more

Paris-based medtech startup Metyos, led by Alexandre Boulanger and co-founder Olga Chashchina, is pioneering a novel approach to chronic kidney disease (CKD) management with its innovative biowearable technology. Departing from Boulanger's prior work in self-balancing exoskeletons, Metyos is now focusing on a lightweight, arm-worn patch designed for real-time monitoring of CKD biomarkers, enabling remote patient management. Chashchina's personal experience with a chronic health condition and Boulanger's interest in nutrition and biochemistry tracking converged to inspire the creation of this u ..read more

ROOK, the Wearable Health Data API, emerges as a groundbreaking innovation in the realm of real-time health monitoring. In a fast-paced world where health and wellness are paramount concerns, ROOK promises to redefine how individuals manage their well-being by seamlessly tracking and analyzing vital signs, activity levels, and overall health status in real time. By leveraging the power of wearable technology and advanced data analytics, ROOK empowers users to make proactive decisions about their lifestyle, facilitating personalized health monitoring experiences tailored to individual needs and ..read more

Baird Medical, a leading medical device company, has obtained a new Class III certificate from China’s National Medical Products Administration (NMPA) for its ceramic thyroid ablation needle. This recognition highlights the needle's innovative design, incorporating rare earth ceramic materials to enhance heat resistance, chemical stability, and electrical insulation. The needle's advanced construction allows for uniform energy distribution during microwave ablation treatments, reducing-edge heating effects and increasing mechanical strength by approximately 30%. The improved material strength ..read more

Polymedco has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its rapid troponin assay, a crucial component of its Pathfast Biomarker Analyzer. This high-sensitivity cardiac troponin I (hs-CTnI-II) assay swiftly detects acute changes in cardiac troponin I concentration, aiding in the diagnosis of myocardial infarction, commonly known as heart attack. Unlike traditional lab tests, which can take over an hour, the Pathfast platform delivers point-of-care results in just 17 minutes, enabling swift diagnosis and early treatment to prevent ischaemic injury. The approval ..read more

Grace Health Technology, renowned for its innovative software solutions in the healthcare sector, has unveiled a groundbreaking application set to transform laboratory operations. On March 29, 2024, the company announced the launch of Live Sample Management, a cutting-edge software designed to revolutionize laboratory technology and enhance efficiency in healthcare settings. The new application represents a significant leap forward in streamlining lab operations, offering automated workflows, real-time analytics, and seamless integration with existing systems, according to Sapphire Villafana ..read more

GE Healthcare Technologies Inc. has successfully finalized the acquisition of MIM Software Inc., integrating its imaging analytics and digital workflow solutions into GE HealthCare's global medical technology portfolio. This strategic move aligns with GE HealthCare's precision care strategy, aiming to enhance care pathways with innovative digital solutions for more precise, connected, and efficient patient care across various disease states. The addition of MIM Software's offerings strengthens GE HealthCare's ability to address healthcare challenges, including staffing shortages and the increa ..read more

Pfizer has terminated one of its two phase 3 trials evaluating inclacumab, a monoclonal antibody aimed at treating sickle cell disease, due to slow recruitment. The THRIVE trials, part of a program initiated to assess inclacumab's safety and efficacy in reducing vaso-occlusive crises, faced challenges with poor accrual, resulting in only 72 out of an expected 280 patients being enrolled before the study concluded in November 2023. Despite the setback, Pfizer remains determined to secure market approval for inclacumab by 2026. The company's spokesperson emphasized that the termination does not ..read more

PharmAla Biotech Holdings Inc., a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, has announced a binding sales agreement with Numinus Wellness Inc. The agreement entails providing PharmAla's GMP LaNeo MDMA for a prospective clinical trial, highlighting LaNeo as the preferred drug product for MDMA clinical trials globally and for prescribers alike. With a focus on alleviating the backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, PharmAla aims to advance research in the psychedelics industry while develo ..read more